$285M
The private financing round was led by TCGX and Aisling Capital to fund clinical trials and commercial planning.
CP
COMPASS Pathways
Developing synthetic psilocybin formulations for treatment resistant mental health conditions.
London, UK—Founded 2016
$285MTotal raised
A London based biotechnology enterprise developing psilocybin therapies for mental health conditions.
Categories
Founders
GG
George Goldsmith
LW
Lars Wilde
EM
Ekaterina Malievskaia